Navigation Links
XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Date:2/7/2008

VALLEY COTTAGE, N.Y., Feb. 7 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) announced today that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the 10th Annual BIO CEO & Investor Conference. Mr. Bentsur will present an overview of the Company including a discussion of Bicifadine, the Company's late-stage clinical compound for the treatment of diabetic neuropathic pain. Mr. Bentsur's presentation will take place on Wednesday, February 13, 2008 at 1:15 pm EST at the Waldorf Astoria Hotel in New York City.

A live webcast of the presentation will be available at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=XTL&item_id=175250 2. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT XTL BIOPHARMACEUTICALS LTD. XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL is also developing novel pre-clinical HCV small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (Nasdaq: XTLB; TASE: XTL).


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
2. Nabi Biopharmaceuticals to Present at the BMO Capital Markets Focus on Healthcare Conference
3. China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results
4. Nabi Biopharmaceuticals Stockholders Approve Asset Sale
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals Proposed Asset Sale
7. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 9th Annual Health Care Conference
8. XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals Announces Mailing of Definitive Proxy Statement and Release Date of Third Quarter 2007 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Allentown, PA (PRWEB) , ... August 15, 2017 ... ... and encrypted shopping cart. Now mobile responsive, the new website makes it ... lab or anywhere in between. Users can now find detailed product information, educational ...
(Date:8/11/2017)... San Antonio, Texas (PRWEB) , ... August 11, 2017 , ... ... launching a rebranding campaign this month that will incorporate important key elements including a ... to thank the community that has supported them, Bill Miller has partnered with the ...
(Date:8/10/2017)... Yorba Linda, Ca (PRWEB) , ... August 09, ... ... and exosomes for regenerative medicine applications in the clinic is here. The team ... secreted EVs present in conditioned medium for clinical studies. , Dr. Travis ...
(Date:8/10/2017)... ... August 10, 2017 , ... SPIE, the ... Ltd. as its exclusive sales representative for SPIE Journals in Japan. Kinokuniya has ... Digital Library in Japan. , “We look forward to expanding our relationship with ...
Breaking Biology Technology:
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
Breaking Biology News(10 mins):